What is Arcus Biosciences's market cap?

Arcus Biosciences (RCUS) has a market capitalization of $3.5B and trades on NYSE.

What is Arcus Biosciences's revenue and profitability?

Arcus Biosciences generated $236.0M in trailing twelve-month revenue with a net loss of $369.0M, representing a net margin of -156.4%, with free cash flow of -$489.0M. These figures are based on the Q1 2026 filing.

Who are Arcus Biosciences's competitors?

Arcus Biosciences's key competitors include Regeneron Pharmaceuticals, Inc., Merck & Co., Inc., Bristol-Myers Squibb Company, and others. These companies compete in similar markets and product categories.

Who does Arcus Biosciences partner with?

Arcus Biosciences's notable partners include Gilead Sciences, Inc., Taiho Pharmaceutical Co., Ltd., WuXi Biologics Ireland Limited, and others.

Where is Arcus Biosciences headquartered?

Arcus Biosciences is headquartered in United States of America and employs approximately 577 people. It has been publicly traded since 2018.

Arcus Biosciences

RCUS

Market cap

$3.5B+251%

Revenue$236.0M+67.4%

Net income-$369.0M+5.6%

Free cash flow-$489.0M-46.4%

EPS (diluted)-$3.19+23.9%

Trailing twelve months · change vs. prior year

Table of contents

Earnings

Q1 2026 report

May 5, 2026

Revenue$17.0MMiss by $12.5M EPS-$1.02Miss by $0.10

Read the full report

Next report

Aug 5, 2026 (In 1 week)

Revenue estimate$22.2M

EPS estimate-$0.89

Financials

Q1 2026

Income statement

See full

Revenue$17.0M-39.3%

Operating income-$134.0M-9.8%

Net income-$128.0M-14.3%

EPS (diluted)-$1.02+10.5%

Balance sheet

See full

Cash & equivalents$201.0M+4.7%

Total debt$113.0M+88.3%

Total equity$524.0M-1.3%

Total assets$997.0M-13.8%

Cash flow

See full

Operating cash flow-$138.0M-4.5%

CapEx--100%

Free cash flow-$138.0M-3.8%

Valuation & ratios

Valuation

See full

Market cap$3.5B+251%

Enterprise value$3.41B+278%

P/S14.8×+10.9×

Profitability

See full

Operating margin-168.6%-52.7pp

Net margin-156.4%-47.5pp

FCF margin-207.2%—

Returns & leverage

See full

Return on equity-70%+8.4pp

Debt / equity0.2×+0.1×

Current ratio4×-1.3×

Segments

By segment

See full

Reportable segment$17.0M-39.3%

By product

See full

R&D services$2.0M0.0%

Competitors

By market cap

AbbVie$453.91B+36.3%

Merck & Co.$322.95B+53.0%

Bristol-Myers Squibb$127.75B+32.1%

Regeneron Pharmaceuticals$69.9B+16.0%

Arcus Biosciences$3.5B+236%

Immunome$2.6B+171%

Zentalis Pharmaceuticals, Inc.$321.1M+210%

Coherus BioSciences$225.2M+81.5%

By revenue growth

Arcus Biosciences+67.4%

AbbVie+9.5%

Regeneron Pharmaceuticals+5.9%

Merck & Co.+2.9%

Bristol-Myers Squibb+1.8%

Immunome-63.3%

By net margin

Regeneron Pharmaceuticals29.65%-2.3pp

Bristol-Myers Squibb15.01%+3.8pp

Merck & Co.13.59%-13.7pp

AbbVie5.79%-1.5pp

Arcus Biosciences-156.36%+121pp

Immunome-5,593.85%-3,719pp

Profile

Arcus Biosciences is a late clinical-stage biopharmaceutical company dedicated to discovering and developing differentiated small molecules and antibodies for cancer, inflammatory, and autoimmune diseases. The company leverages an internal small-molecule discovery engine to create a pipeline of potential best-in-class therapies, often designed to improve upon validated biological targets. Its primary value proposition lies in its ability to advance multiple high-potential programs through strategic global collaborations and internal development capabilities.

Competitive position

Arcus maintains a strong competitive position through a significant strategic partnership with Gilead Sciences and a pipeline of molecules designed for superior pharmacokinetic profiles compared to existing approved therapies.

GeographiesUnited States, Japan, Asia, Global

Customer segmentsBiopharmaceutical partners, Clinical trial participants, Specialty healthcare providers

Business modelR&D, Licensing and Royalties, Collaborative Development

SuppliersContract Manufacturing Organizations (CMOs), Contract Research Organizations (CROs), Academic research institutions, Specialized API suppliers

CustomersGilead Sciences, Taiho Pharmaceutical, Specialty pharmacies, Hospitals and oncology clinics

CountryUnited States of America

Listed2018

Employees577.0

CEOTerry J. Rosen

SectorHealthcare

IndustryBiotechnology

Websitearcusbio.com

FilingsSEC EDGAR

Ask your AI about Arcus Biosciences.

Connect your AI assistant and dig into the numbers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Arcus Biosciences's market cap?: Arcus Biosciences (RCUS) has a market capitalization of $3.5B and trades on NYSE.
What is Arcus Biosciences's revenue and profitability?: Arcus Biosciences generated $236.0M in trailing twelve-month revenue with a net loss of $369.0M, representing a net margin of -156.4%, with free cash flow of -$489.0M. These figures are based on the Q1 2026 filing.
Who are Arcus Biosciences's competitors?: Arcus Biosciences's key competitors include Regeneron Pharmaceuticals, Inc., Merck & Co., Inc., Bristol-Myers Squibb Company, and others. These companies compete in similar markets and product categories.
Who does Arcus Biosciences partner with?: Arcus Biosciences's notable partners include Gilead Sciences, Inc., Taiho Pharmaceutical Co., Ltd., WuXi Biologics Ireland Limited, and others.
Where is Arcus Biosciences headquartered?: Arcus Biosciences is headquartered in United States of America and employs approximately 577 people. It has been publicly traded since 2018.